Abstract
For therapy of cutaneous lupus erythematosus the precise classification of the clinical subset is necessary. The most frequently found LE subsets are chronic discoid LE (CDLE) and subacute cutaneous LE (SCLE). Extension of the cutaneous lesions and presence of visceral involvement are criteria for therapy choice. Basic therapeutics for cutaneous LE are antimalarials (chloroquine, hydroxychloroquine) alone or in combination with systemic corticosteroids. For visceral involvement others than arthralgia/arthritis azathioprin is the first line therapy. In 80-90% of the patients disease can be controlled by these standard therapies. In the remaining cases oral retinoids, thalidomide, methotrexate or diaminodiphenylsulfon can be tried. Recently, a few case reports have been published on a good therapeutic effect of local tacrolimus and systemic mycophenolate mofetil in cutaneous LE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
